The Dr. Reddy’s Laboratories Ltd. (RDY) Receives $41.90 Consensus Target Price from Analysts

The Dr. Reddy’s Laboratories Ltd. (RDY) Receives $41.90 Consensus Target Price from Analysts

Shares of Dr. Reddy’s Laboratories Ltd. (NYSE:RDY) have earned a consensus recommendation of “Hold” from the seven ratings firms that are presently covering the stock. Three research analysts have rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating on the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $41.90.

A number of research firms recently weighed in on RDY. Zacks Investment Research raised shares of Dr. Reddy’s Laboratories from a “sell” rating to a “hold” rating in a research report on Monday, October 24th. TheStreet raised shares of Dr. Reddy’s Laboratories from a “hold” rating to a “buy” rating in a research report on Monday, November 14th.

Hedge funds have recently made changes to their positions in the stock. Glenmede Trust Co. NA boosted its stake in shares of Dr. Reddy’s Laboratories by 16.3% in the second quarter. Glenmede Trust Co. NA now owns 2,570 shares of the company’s stock worth $130,000 after buying an additional 360 shares in the last quarter. First Mercantile Trust Co. purchased a new stake in shares of Dr. Reddy’s Laboratories during the third quarter worth approximately $158,000. Wedbush Securities Inc. purchased a new stake in shares of Dr. Reddy’s Laboratories during the third quarter worth approximately $209,000. Johnson Investment Counsel Inc. purchased a new stake in shares of Dr. Reddy’s Laboratories during the second quarter worth approximately $214,000. Finally, Alps Advisors Inc. boosted its stake in shares of Dr. Reddy’s Laboratories by 1.0% in the third quarter. Alps Advisors Inc. now owns 7,097 shares of the company’s stock worth $329,000 after buying an additional 67 shares in the last quarter. Hedge funds and other institutional investors own 16.03% of the company’s stock.

Shares of Dr. Reddy’s Laboratories (NYSE:RDY) opened at 43.76 on Thursday. The company has a market cap of $7.25 billion, a PE ratio of 47.05 and a beta of 0.61. The company has a 50-day moving average of $45.51 and a 200-day moving average of $46.93. Dr. Reddy’s Laboratories has a 1-year low of $40.67 and a 1-year high of $54.73.

Dr. Reddy’s Laboratories Company Profile

Dr. Reddy’s Laboratories Limited is a pharmaceutical company that is engaged in providing medicines. The Company operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment includes manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics).

Related posts

Leave a Comment